Complete financial analysis of Integra LifeSciences Holdings Corporation (IART) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Integra LifeSciences Holdings Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Nichireki Co., Ltd. (5011.T) Income Statement Analysis – Financial Results
- Sumitomo Forestry Co., Ltd. (1911.T) Income Statement Analysis – Financial Results
- Hanwei Energy Services Corp. (HE.TO) Income Statement Analysis – Financial Results
- Oxford Lane Capital Corp. 6.75% Notes due 2031 (OXLCL) Income Statement Analysis – Financial Results
- Raya Holding For Financial Inve (EGS690C1C010.CA) Income Statement Analysis – Financial Results
Integra LifeSciences Holdings Corporation (IART)
About Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.54B | 1.56B | 1.54B | 1.37B | 1.52B | 1.47B | 1.19B | 992.08M | 882.73M | 928.31M | 836.21M | 830.87M | 780.08M | 732.07M | 682.49M | 654.60M | 550.46M | 419.30M | 277.94M | 229.83M | 185.60M | 112.63M | 93.44M | 64.99M | 42.50M | 17.50M | 14.70M | 13.10M | 10.20M |
| Cost of Revenue | 653.18M | 587.36M | 597.81M | 520.83M | 564.68M | 571.50M | 435.51M | 349.09M | 326.54M | 352.80M | 334.09M | 314.43M | 299.15M | 268.19M | 244.92M | 252.83M | 214.67M | 168.31M | 105.54M | 87.30M | 70.60M | 45.77M | 36.01M | 26.82M | 21.80M | 6.10M | 5.20M | 4.70M | 3.50M |
| Gross Profit | 888.39M | 970.31M | 944.64M | 851.03M | 952.88M | 900.95M | 752.73M | 642.99M | 556.19M | 575.50M | 502.13M | 516.44M | 480.93M | 463.88M | 437.57M | 401.78M | 335.79M | 250.98M | 172.40M | 142.53M | 115.00M | 66.85M | 57.43M | 38.17M | 20.70M | 11.40M | 9.50M | 8.40M | 6.70M |
| Gross Profit Ratio | 57.63% | 62.29% | 61.24% | 62.03% | 62.79% | 61.19% | 63.35% | 64.81% | 63.01% | 62.00% | 60.05% | 62.16% | 61.65% | 63.37% | 64.11% | 61.38% | 61.00% | 59.86% | 62.03% | 62.02% | 61.96% | 59.36% | 61.46% | 58.74% | 48.71% | 65.14% | 64.63% | 64.12% | 65.69% |
| Research & Development | 174.59M | 101.19M | 93.05M | 77.38M | 79.57M | 78.04M | 63.46M | 58.16M | 50.90M | 51.60M | 52.09M | 51.01M | 51.45M | 48.11M | 44.28M | 60.50M | 30.66M | 25.73M | 11.96M | 14.12M | 12.81M | 8.30M | 7.99M | 7.52M | 8.70M | 8.40M | 6.40M | 6.30M | 5.20M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 690.75M | 624.10M | 455.63M | 415.76M | 445.97M | 394.25M | 373.11M | 358.13M | 305.06M | 281.10M | 281.00M | 225.19M | 157.71M | 98.27M | 99.36M | 59.46M | 40.59M | 32.37M | 43.85M | 22.20M | 15.80M | 20.30M | 9.60M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 592.64M | 616.32M | 637.45M | 594.53M | 687.60M | 690.75M | 624.10M | 455.63M | 415.76M | 445.97M | 394.25M | 373.11M | 358.13M | 305.06M | 281.10M | 281.00M | 225.19M | 157.71M | 98.27M | 99.36M | 59.46M | 40.59M | 32.37M | 43.85M | 22.20M | 15.80M | 20.30M | 9.60M | 6.10M |
| Other Expenses | 69.16M | 13.88M | 16.91M | 27.76M | 27.03M | 8.29M | 1.35M | 845.00K | 4.59M | -763.00K | -1.80M | -721.00K | 16.43M | 12.02M | 14.36M | 12.88M | 12.65M | 8.80M | 6.06M | 4.27M | 3.08M | -3.55M | 2.78M | 5.18M | 2.20M | 1.30M | 1.80M | 2.00M | 1.40M |
| Operating Expenses | 836.39M | 731.39M | 747.41M | 699.66M | 794.20M | 789.95M | 707.92M | 527.65M | 476.61M | 509.96M | 459.04M | 442.66M | 426.02M | 365.19M | 339.75M | 354.37M | 268.50M | 192.24M | 116.29M | 117.75M | 75.36M | 45.34M | 43.14M | 56.55M | 33.10M | 25.50M | 28.50M | 17.90M | 12.70M |
| Cost & Expenses | 1.43B | 1.32B | 1.35B | 1.22B | 1.36B | 1.36B | 1.14B | 876.74M | 803.15M | 862.76M | 793.12M | 757.09M | 725.17M | 633.37M | 584.66M | 607.19M | 483.17M | 360.55M | 221.83M | 205.05M | 145.95M | 91.11M | 79.16M | 83.37M | 54.90M | 31.60M | 33.70M | 22.60M | 16.20M |
| Interest Income | 17.20M | 11.92M | 6.74M | 9.30M | 10.78M | 2.80M | 255.00K | 24.00K | 13.00K | 168.00K | 443.00K | 1.21M | 465.00K | 225.00K | 631.00K | 2.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 51.38M | 49.59M | 50.40M | 71.58M | 53.96M | 64.68M | 35.02M | 25.80M | 23.52M | 21.97M | 19.79M | 22.24M | 27.64M | 18.36M | 23.23M | 30.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 123.51M | 121.12M | 123.67M | 118.99M | 114.70M | 115.70M | 88.90M | 72.67M | 9.95M | 12.40M | 47.01M | 18.54M | 16.43M | 39.17M | 39.69M | 33.15M | 27.04M | 21.48M | 13.22M | 11.59M | 9.04M | 7.16M | 6.26M | 5.18M | 2.20M | 1.30M | 1.80M | 2.00M | 1.40M |
| EBITDA | 274.01M | 391.10M | 366.33M | 267.93M | 231.03M | 241.04M | 135.23M | 231.73M | 195.59M | 172.24M | 40.07M | 116.46M | 106.31M | 139.64M | 136.07M | 79.34M | 67.29M | 58.74M | 69.33M | 36.37M | 48.69M | 25.81M | 20.54M | -13.21M | -12.40M | -16.60M | -17.20M | -7.50M | -4.60M |
| EBITDA Ratio | 17.77% | 17.77% | 15.57% | 14.06% | 13.57% | 9.73% | 5.62% | 13.11% | 10.66% | 8.33% | 10.61% | 11.17% | 9.21% | 18.86% | 20.24% | 12.44% | 16.60% | 19.61% | 25.21% | 14.08% | 14.39% | 22.91% | 15.97% | -32.65% | -34.12% | -83.43% | -130.61% | -71.76% | 144.12% |
| Operating Income | 111.53M | 238.92M | 197.23M | 151.37M | 178.98M | 111.00M | 44.80M | 115.34M | 79.59M | 65.54M | -3.64M | 73.78M | 54.91M | 98.69M | 97.82M | 47.41M | 67.29M | 58.74M | 56.11M | 24.78M | 39.65M | 19.19M | 14.29M | -18.38M | -12.40M | -14.10M | -19.00M | -9.50M | -6.00M |
| Operating Income Ratio | 7.23% | 15.34% | 12.79% | 11.03% | 11.79% | 7.54% | 3.77% | 11.63% | 9.02% | 7.06% | -0.44% | 8.88% | 7.04% | 13.48% | 14.33% | 7.24% | 12.22% | 14.01% | 20.19% | 10.78% | 21.36% | 17.04% | 15.29% | -28.29% | -29.18% | -80.57% | -129.25% | -72.52% | -58.82% |
| Total Other Income/Expenses | -30.46M | -25.03M | 17.45M | -57.85M | -33.66M | -53.60M | -33.42M | -24.93M | -18.92M | -24.88M | -21.15M | -21.75M | -26.42M | -16.58M | -24.67M | -16.41M | -7.23M | -10.44M | -1.00M | 3.23M | 3.54M | 3.54M | 1.26M | 7.54M | 7.43M | 5.26M | 2.00M | 1.90M | -19.30M |
| Income Before Tax | 81.07M | 213.89M | 214.68M | 93.52M | 60.10M | 57.40M | 11.39M | 90.41M | 60.67M | 42.98M | -24.79M | 52.03M | 28.49M | 82.11M | 73.15M | 31.01M | 60.06M | 48.31M | 55.10M | 28.01M | 43.19M | 22.73M | 15.54M | -10.85M | -7.80M | -12.30M | -17.00M | -7.60M | -25.30M |
| Income Before Tax Ratio | 5.26% | 13.73% | 13.92% | 6.82% | 3.96% | 3.90% | 0.96% | 9.11% | 6.87% | 4.63% | -2.96% | 6.26% | 3.65% | 11.22% | 10.72% | 4.74% | 10.91% | 11.52% | 19.83% | 12.19% | 23.27% | 20.18% | 16.63% | -16.69% | -18.35% | -70.29% | -115.65% | -58.02% | -248.04% |
| Income Tax Expense | 13.33M | 33.34M | 45.60M | -40.37M | 9.90M | -3.40M | -53.36M | 15.84M | 53.82M | 8.98M | -7.81M | 10.83M | 505.00K | 16.45M | 22.20M | -3.93M | 26.59M | 18.90M | 17.91M | 10.81M | 16.33M | -12.55M | -10.86M | 108.00K | -1.80M | -1.80M | -2.00M | -2.00M | 19.40M |
| Net Income | 67.74M | 180.55M | 169.08M | 133.89M | 50.20M | 60.80M | 64.74M | 74.56M | -3.52M | 34.00M | -16.98M | 41.20M | 27.99M | 65.67M | 50.96M | 34.93M | 33.47M | 29.41M | 37.19M | 17.20M | 26.86M | 35.28M | 26.16M | -11.43M | -6.00M | -12.30M | -17.00M | -7.50M | -25.40M |
| Net Income Ratio | 4.39% | 11.59% | 10.96% | 9.76% | 3.31% | 4.13% | 5.45% | 7.52% | -0.40% | 3.66% | -2.03% | 4.96% | 3.59% | 8.97% | 7.47% | 5.34% | 6.08% | 7.01% | 13.38% | 7.48% | 14.47% | 31.32% | 28.00% | -17.58% | -14.12% | -70.29% | -115.65% | -57.25% | -249.02% |
| EPS | 0.87 | 2.18 | 2.00 | 1.58 | 0.59 | 0.73 | 0.83 | 1.00 | -0.05 | 0.52 | -0.30 | 0.74 | 0.52 | 1.11 | 0.88 | 0.49 | 0.61 | 0.50 | 0.62 | 0.28 | 0.46 | 0.61 | 0.54 | -0.33 | -0.18 | -0.38 | -0.58 | -0.27 | -1.21 |
| EPS Diluted | 0.84 | 2.16 | 1.98 | 1.57 | 0.58 | 0.72 | 0.82 | 0.94 | -0.05 | 0.52 | -0.29 | 0.72 | 0.48 | 1.09 | 0.87 | 0.48 | 0.56 | 0.49 | 0.57 | 0.28 | 0.43 | 0.57 | 0.47 | -0.33 | -0.18 | -0.38 | -0.58 | -0.27 | -1.21 |
| Weighted Avg Shares Out | 78.17M | 83.00M | 84.70M | 84.65M | 85.64M | 82.86M | 78.39M | 74.72M | 73.88M | 65.48M | 56.83M | 55.90M | 53.66M | 59.10M | 58.08M | 55.56M | 55.42M | 58.60M | 60.39M | 60.13M | 58.14M | 58.04M | 46.71M | 35.11M | 33.60M | 32.28M | 29.57M | 28.11M | 20.99M |
| Weighted Avg Shares Out (Dil) | 80.34M | 83.52M | 85.49M | 85.23M | 86.49M | 84.45M | 79.12M | 79.19M | 73.88M | 65.92M | 57.60M | 57.03M | 58.99M | 60.30M | 58.58M | 56.76M | 59.16M | 65.49M | 69.13M | 62.20M | 66.21M | 61.79M | 55.59M | 35.11M | 34.12M | 32.28M | 29.57M | 28.11M | 20.99M |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
NEW YORK , Nov. 11, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART). Such investors are advised to contact Robert S.
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Integra LifeSciences Holdings Corporation (IART)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Integra LifeSciences Holdings Corporation (“Integra”...
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Integra LifeSciences Holdings Corporation(IART) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Nov. 9, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on...
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Integra LifeSciences Holdings Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 13, 2023 - (NASDAQ: IART)
NEW YORK , Nov. 7, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Integra LifeSciences Holdings Corporation. Shareholders who purchased shares of IART during the class period listed are encouraged to contact the firm regarding possible...
IART Investors Have Opportunity to Lead Integra LifeSciences Holdings Corporation Securities Fraud Lawsuit
BENSALEM, Pa. , Nov. 7, 2023 /PRNewswire/ -- Law Offices of Howard G.
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Integra LifeSciences Holdings Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - IART
NEW YORK , Nov. 6, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Integra LifeSciences Holdings Corporation (NASDAQ: IART) between March 11, 2019 and May 22, 2023, both dates inclusive...
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Integra Investors of a Lead Plaintiff Deadline of November 13, 2023
NEW YORK , Nov. 6, 2023 /PRNewswire/ -- Attention Integra LifeSciences Holdings Corporation ("Integra") (NASDAQ: IART) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between March 11,...
INTEGRA LIFESCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Integra LifeSciences Holdings Corporation - IART
NEW ORLEANS , Nov. 3, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 13, 2023 to file lead plaintiff applications in a securities class action lawsuit against Integra LifeSciences Holdings Corporation (NasdaqGS:...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART). Such investors are advised to contact Robert S.
IART Investors Have Opportunity to Lead Integra LifeSciences Holdings Corporation Securities Fraud Lawsuit
LOS ANGELES , Nov. 3, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:...
Source: https://incomestatements.info
Category: Stock Reports